Some researchers explore microdosing tirzepatide at levels below the standard starting dose, though this approach falls outside typical prescribing guidelines
A 2% reduction represents substantial improvement in glycemic control, often enough to reduce or eliminate diabetes medication requirements
GPCR dynamics: structures in motion
[168] [169] In June 2025, the European Medicines Agency recommended that the product information for semaglutide medicines be updated to include non-arteritic anterior ischemic optic neuropathy (NAION) as a very rare side effect, [170] while the World Health Organization concluded that the risk management plan for semaglutide should be revised to include NAION as a potential risk
If prescribed, members receive ongoing medical oversight along with tools that help them manage side effects, track doses, and understand how the medication fits into their daily life
Like GLP-1 medications, co-agonists can lower blood sugar